A Randomized, Double-blind, Placebo-controlled, Single Dose-escalation, Phase Ia Clinical Study to Evaluate the Safety and Pharmacokinetics of RBD1016 in Healthy Subjects
Latest Information Update: 27 Apr 2022
At a glance
- Drugs RBD 1016 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Suzhou Ribo Life Science
- 24 Apr 2022 Status changed from recruiting to completed.
- 12 Apr 2021 Status changed from not yet recruiting to recruiting.
- 04 Jan 2021 New trial record